ClinicalTrials.gg
Not yet recruitingNCT06668155Updated Nov 10, 2026

ACLR: Isolated Autograft vs Allograft With Lateral Extra-articular Tenodesis

An interventional study of Autograft Group and Allograft with LET Group in ACL Deficient Knee, sponsored by University of Alabama at Birmingham. Not yet recruiting. Open to participants aged 14 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
14 Years to 89 Years
Sex
All
01

Study summary

This study seeks to evaluate the utility of non-irradiated allograft tissue with lateral extra-articular tenodesis (LET) in the setting of anterior cruciate ligament reconstruction (ACLR).

Read the detailed description

While ACL injuries are among the most common sports medicine injuries treated arthroscopically, significant debate surrounds the choice of graft used in ACLR. While graft choice has been studied extensively, allografts have been shown to have a slightly increased risk of failure than autografts. However, these differences become less pronounced with non-irradiated allografts that have not undergone chemical processing or with slower rehabilitation timelines. Allografts also show poorer graft maturation on MRI. The use of allografts may avoid the donor site morbidities associated with autograft procedures such as pain, donor site weakness, and increased surgical duration. Previous studies have documented a high prevalence of extensor and flexor weakness following autograft ACLR, with deficits in flexor strength following hamstring autograft lasting up to 12 months and extensor strength deficits at 24 months following quadriceps tendon autograft ACLR. Limiting these morbidities may allow a more predictable return to activity and improve patient satisfaction following ACLR. Despite the benefits, concern remains regarding the use of allografts in higher demand patients. However, some studies of patients undergoing ACLR show similar results between allografts and autografts.

Despite advancements in ACLR techniques, retear rates and return-to-play rates remain unsatisfactory in specific populations. Recent investigations into the persistence of anterolateral rotatory laxity in patients have led to an increased focus on the role of the anterolateral complex for knee stability. Specifically, LET has grown in popularity in the setting of ACLR. Previous studies have demonstrated that the addition of LET may improve clinical outcomes when performed in conjunction with an ACLR, possibly by decreasing post-operative pivot shift, tibial translation, and retear rates.

No study to date has compared non-irradiated allografts augmented with LET to autografts for ACLR in a randomized controlled trial fashion. This proposed study aims to understand the utility of allografts in ACLR when combined with LET.

02

Conditions studied

  • ACL Deficient Knee
03

In context

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACL deficient knee that are indicated for autograft ACLR

Exclusion criteria

Exclusion Criteria:

  • concomitant ligamentous injury that require surgery
  • revision ACLR
  • patients indicated for LET
  • patients with previous knee surgery
  • patients with cancer
  • patients who are pregnant or nursing
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Assignment 0

    Procedure: Autograft Group

  • Active comparator
    Assignment 1

    Procedure: Allograft with LET Group

Interventions

  • ProcedureAutograft Group

    If assigned the autograft group, the surgeon will choose either bone patella tendon bone (BPTB) or all soft tissue quadriceps tendon for the graft. The graft choice will be based upon surgeon preference.

  • ProcedureAllograft with LET Group

    The allograft used will be a non-irradiated quadriceps tendon with bone plug allograft with a donor age less than 45 years.

06

What researchers measure

Primary outcomes

  1. Anterior Tibial Translation

    KT-1000 measurement

    Time frame: 9 month post procedure

  2. Quadricep and Hamstring Strength

    Isometric Biodex Testing

    Time frame: 5-8 months post procedure and 9-15 months post procedure

  3. Magnetic Resonance Imaging

    Graft signal interpretation

    Time frame: 9-15 months post procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2028; primary completion for Nov 2030, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Oct 31, 2024
StartEst.
Jan 2028
Primary completionEst.
Nov 2030
CompletionEst.
Jun 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06668155
Responsible party
Amit Momaya (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Oct 31, 2024
Start date
Jan 2028 (estimated)
Primary completion
Nov 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Amit Momaya, MD
Contact
momaya@uab.edu
205-930-8339
Amit Momaya, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion